[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rare-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rare-disease":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604280","performance-indicators-and-impact-on-the-care-pathway-of-sequencing-on-the-seqoia-and-auragen-seqogen-platforms-for-oncology-patients-100604280",false,"NCT07147465","Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients","Indicateurs de Performance et Impact Sur le Parcours de Soins du Séquençage Sur Les Plateformes Seqoia et Auragen (Seqogen) Pour Les Patients en Oncologie","SONCO","Inclusion Criteria:\n\n* Patients diagnosed with cancer and referred for high-throughput sequencing\n* Sequencing pre-indication validated: Patients for whom the pre-indication for sequencing the genome, exome, and RNA has been validated by the upstream RCP (Multidisciplinary Tumor Board) since January 1, 2021.\n\nConsent for data reuse: Patients who have agreed to the reuse of their medical and genomic data for research purposes and have not opposed this use.\n\nExclusion Criteria:\n\n* Opposition to data reuse, unvalidated upstream RCP","ALL",{"count":19,"type":20},3149,"ESTIMATED","OBSERVATIONAL","As part of the French Genomic Medicine Plan 2025 (FGM), the SeqOIA and AURAGEN platforms were selected to perform high-throughput genomic sequencing.\n\nThe SONCO (Sequencing Oncology Cohort) project combines their medical and economic evaluations into a single national cohort. Its objective is to assess the impact of genomic sequencing on care pathways and treatment recommendations by collecting indicators related to quality, turnaround time, and patient information. Clinical data are gathered from molecular tumor board reports (via SPICE and HYGEN) and from hospital medical records.\n\nThis cohort is intended to support public health decision-making and help anticipate the organization of future genomic platforms.",[24,25,26,27],"Cancer","NGS","Tumor","RARE DISEASE",[29,30,31,32,33],"Oncology","genomic medecine","cancer","rare diseases","next-generation sequencing","RECRUITING","2025-08-22",{"date":37,"type":38},"2025-08-29","ACTUAL",{"date":40,"type":38},"2025-07-01",{"date":42,"type":20},"2026-09-30",{"name":44,"class":45},"Assistance Publique - Hôpitaux de Paris","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100454877","longitudinal-registry-including-patients-treated-with-heavy-particles-100454877","NCT05203250","Longitudinal Registry Including Patients Treated With Heavy Particles","CNAO REgistry triAL - REGAL","Inclusion Criteria:\n\n* Patients treated with heavy particles at Fondazione CNAO, Pavia\n* Patients who have the ability to understand and be willing to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients or legal guardians who are unable to understand informed consent document",{"count":55,"type":20},3000,"50 Years","The purpose of this registry is to collect retrospective and prospective standardized data of patients treated with particle therapy, either with protons or carbon ions, at the National Center for Oncological Hadrontherapy (CNAO) based in Pavia.\n\nBy keeping track of the patients treated, it will allow the investigators to periodically analyze and evaluate data collected of daily clinical activity. This will help gathering more information on the results of particle therapy and will provide the basis for in depth evaluation of patients' outcome with respect to the delivered treatment.",[24,29,59,60,61,62],"Radiation Exposure","Radiotherapy Side Effect","Radiation Toxicity","Rare Disease",[64,29,24,65,66,67,68,69],"Hadrontherapy","Radiotherapy","Protons","Carbon Ions","Heavy ions","Rare cancer","2025-08-01",{"date":72,"type":38},"2025-08-06",{"date":74,"type":38},"2021-06-04",{"date":76,"type":20},"2071-06-04",{"name":78,"class":45},"CNAO National Center of Oncological Hadrontherapy",1]